Archive
Brokers: Jefferies foresees fall in consumer confidence
Lots of dark clouds are gathering for retailers, judging by the latest retail review from Jefferies. Also covered: GlaxoSmithKline, Aureus Mining, Spire Healthcare Group
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 34 of 38
Most followed: Donald Trump, Gulf Keystone Ltd, GlaxoSmithKline, Rio Tinto, Sirius Minerals, Tesco
Tesco managers told to be nicer, Donald Trump a 'global risk' and FTSE 100 casualties.
GlaxoSmithKline PLC boss to quit in 2017 amid shake-up talk
Drug giant says Andrew Witty will go in March 2017
Archive
AstraZeneca PLC lacks catalysts for 2016 - Jefferies
Broker Jefferies has cut its rating on drugs giant AstraZeneca PLC to 'hold' from 'buy' saying there's a lack of catalysts in 2016 to re-rate shares.
FTSE 100 closes Monday’s trading flat
The blue-chip benchmark ended February a solitary point higher than Friday’s closing price.
London market moves lower but investors shop at Morrisons
The FTSE 100 Index dropped due to China’s slowdown, Brexit fears and commodity uncertainty
GlaxoSmithKline launches hunt for new chief executive
Drug group is said to have kicked off succession planning, but it is in no rush to replace Witty
OR Productivity lines up pre-IPO funding
OR Productivity aims to become a go-to company for the commercialisation of minimally invasive medicine
Archive
Footsie closes lower as oil and Standard Chartered weigh
Footsie closed 1.25% down as oil weighed along with the results from Standard Chartered..
London shares fall on mining woe and business's EU exit fears
Footsie companies warned that EU exit could cost UK jobs and investment
Archive
Jefferies downgrades targets on Glaxo and Astra
US heavyweight Jefferies looks at global pharma today and downgraded Glaxo and AstraZeneca...
Archive
FTSE 100 makes good ground despite Brexit talk
Footsie was buoyed by a good start to the week;s trading on Wall Street
FTSE100 posts solid gains as Brexit talks slays sterling
FTSE 100 climbed 76 points to 6,026 despite a tough day for the pound
Glaxo fined £38mln for Seroxat deal 15 years ago
The CMA levied the £45mln penalties for ‘pay and delay’ agreements
Archive
FTSE100 finishes down as Lloyds slashes jobs
FTSE100 continued lower on Wednesday to finish almost 1.5% lower..
GlaxoSmithKline gets shot in arm but M&A talk trundles on
Drug company boosted 2015 revenues and achieved better-than-expected dip in earnings
Shares below 5,900 on Asian and Europe economic woes
The FTSE 100 Index, which was 16 points off in earlier trading, fell below the 5900 level
GlaxoSmithKline earnings fall but on track to save £3bn
Drug company confirmed a 2015 ordinary dividend of 80p and special payout of 20p per share
London shares fall after Asian markets end in red
The Footsie fell 16.18 points to 5905 but GlaxoSmithKline got a boost from M&A rumours
Week Ahead: Big oil and big pharma to the fore
Big oil and big pharma will wrestle for the limelight. On the economic front, the big events are the Bank of England's interest rate decision and US non-farm payrolls.